BPC-157 for Tendon Repair: The Complete Evidence Review
- Written by
- Daniel Reyes, PhD
- Medically reviewed by
- Dr. Sarah Lindqvist, MD
- Published
- June 20, 2025
- Updated
- June 20, 2025
- Last medical review
- June 20, 2025
- Reviewer scope
- Metabolic health

BPC-157’s tendon-repair reputation rests on rodent studies — most cited, a rat Achilles transection model where treated tendons showed better fibroblast outgrowth, cell migration, and functional recovery than controls. The proposed mechanism runs through growth-factor and nitric-oxide signaling. No controlled human tendon trial has been published, so human efficacy remains unknown.
What the flagship rat study showed
In transected rat Achilles tendons, BPC-157 exposure improved tendon-fibroblast outgrowth from explants, cell survival under oxidative stress, and migration — with better functional recovery scores in treated animals. Effects appeared with both injected and oral administration in related work.
Mechanistic plausibility
Upregulation of growth-hormone receptor expression on fibroblasts, VEGF-linked angiogenesis, and FAK-paxillin pathway activation have all been reported in vitro. Plausible mechanism raises the prior; it does not substitute for human outcomes.
From rat to human: what is missing
- Any randomized human tendon trial
- Human pharmacokinetics for either route
- Safety data beyond anecdote in an unapproved, compounding-risk-listed compound
- Comparison against loading-based rehab, the actual standard of care
The dosing numbers extrapolated from these studies are dissected in our BPC-157 dosage research and the duration conventions in the cycle-length review. TB-500 is marketed for the same injuries on even thinner data — the TB-500 evidence review covers it. Gauge your actual readiness with the recovery assessment.
Bottom line
Interesting biology, absent clinical proof. Progressive loading protocols remain the only tendon intervention with human evidence. Anyone considering more should be having that conversation with a licensed clinician, not a checkout page.
Frequently asked questions
Does BPC-157 heal tendons in humans?
What did the rat Achilles study actually show?
What actually works for tendon healing?
Questions to ask a licensed clinician
- Has my rehab actually exhausted progressive-loading options?
- What imaging or functional milestones would justify escalation?
References
- Chang CH, Tsai WC, Lin MS, et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. SourcePreclinical
- Sikiric P, Seiwerth S, Rucman R, et al. (2018). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. SourceNarrative review
- US Food and Drug Administration (2023). Certain bulk drug substances for use in compounding that may present significant safety risks. FDA Human Drug Compounding. SourceAgency notice
Related tools
Something incorrect in this guide? Report a correction. Material corrections are noted on the page with the date and nature of the change.
